couter

BHCCFBenchmark Holdings plc

Dec 10, 2026 — Q4 & FY 2026 Earnings Release
Chart by TradingView

The schedule

  • Thu10Dec

    Full-year 2026 results will detail the complete financial impact of the streamlined operating model, providing FY 2027 guidance for the remaining Health and Advanced Nutrition portfolios.

  • Tue22Dec
  • Tue22Dec
  • Tue23Mar

    Q1 2027 earnings will focus on seasonal Advanced Nutrition sales, particularly in the shrimp and marine finfish markets, alongside free cash flow generation to service ongoing debt obligations.

  • Wed14Apr

    Benchmark is anticipated to provide a commercial update on its new water purification and sea lice treatment solutions, including Ectosan Vet and Purisan, across key international markets like Norway and Chile.

  • Tue22Jun

    Q2 2027 earnings will serve as a crucial barometer for the Health segment's margin expansion and the broader commercial adoption of Benchmark's aquaculture sustainability solutions.

Past

  • Thu5Nov

    Management is expected to address the company's distressed 12.4x Net Debt/EBITDA leverage ratio. A potential debt restructuring, dilutive equity raise, or further asset sales will be critical for avoiding liquidity cliffs in 2027.

  • Tue22Sep

    Benchmark Holdings will report Q3 2026 results, providing investors a first comprehensive look at operating margins and cash burn for the Advanced Nutrition and Health segments following the divestiture of its Genetics division.